A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-β inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy

Diabetes Care

Volumn 30, Issue 4, 2007, Pages 896-902

  Casellini, Carolina M ^a   Barlow, Patricia M ^a   Rice, Amanda L ^a   Casey, Melissa ^a   Simmons, Kathryn ^a   Pittenger, Gary ^a   Bastyr III, Edward J ^b,c   Wolka, Anne M ^b   Vinik, Aaron I ^a,d  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PLACEBO; PROTEIN KINASE C; RUBOXISTAURIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DEATH; DIABETES MELLITUS; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUPUYTREN CONTRACTURE; ENZYME ACTIVATION; FEMALE; HEART ATRIUM ENLARGEMENT; HEART MUSCLE ISCHEMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MALE; MICROVASCULAR ISCHEMIA; MORPHOMETRICS; NERVE CONDUCTION; PNEUMONIA; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHOULDER PAIN; SIDE EFFECT; SKIN BLOOD FLOW; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 34147152341     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1699     Document Type: Article

References (42)

1. Vinik AI, Park TS, Stansberry KB, Pittenger GL: Diabetic neuropathies. Diabetologia 43:957-973, 2000
2. Vinik AI, Erbas T, Stasberry KB, Pittenger GL: Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endocrinol Diabetes 109 (Suppl. 2):S451-S473, 2001
3. Al-Shekhlee A, Chelimsky TC, Preston DC: Review: small-fiber neuropathy. Neurologist 8:237-253, 2002
4. Vinik AI, Ullal J, Parson HK, Casellini CM: Diabetic neuropathies: clinical manifestations and current treatment options. Nature Clin Pract Endocrinol Metab 5:269-281, 2006
5. Lacomis D: Small-fiber neuropathy. Muscle Nerve 26:173-188, 2002
6. Resnick HE, Valsania P, Phillips CL: Diabetes mellitus and nontraumatic lower extremity amputation in black and white Americans: the National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study, 1971-1992. Arch Intern Med 159:2470-2475, 1999
7. National Diabetes Information Clearinghouse: Diabetic neuropathies: the nerve damage of diabetes [article online], 2002. Available from http://diabetes.niddk.nih.gov/dm/pubs/neuropathies/. Accessed 26 June 2006
8. Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med 18:945-959, 2001
9. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications JAMA 288:2579-2588, 2002
10. Setter SM, Campbell RK, Cahoon CJ: Biochemical pathways for microvascular complications of diabetes mellitus. Ann Pharmacother 37:1858-1866, 2003
11. Kles K, Vinik AI: Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. Curr Diabetes Rev 2:131-145, 2006
12. Vinik A, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ 3rd, the MBBQ Study Group: Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta inhibitor ruboxistaurin mesylate during a 1-year randomized, placebo-controlled, double-blind clinical trial. Clin Ther 27:1164-1180, 2005
13. Bastyr EJ 3rd, Price KL, Bril V, the MBBQ Study Group: Development and validity testing of the Neuropathy Total Symptom Score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther 27:1278-1294, 2005
14. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC: Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 45:1115-1121, 1995
15. Stansberry KB, Hill MA, Shapiro SA, McNitt PM, Bhatt BA, Vinik AI: Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect. Diabetes Care 20:1711-1716, 1997
16. Vinik AI, Erbas T, Park TS, Pierce KK, Stansberry KB: Methods for evaluation of peripheral neurovascular dysfunction. Diabetes Technol Ther 3:29-50, 2001
17. Colberg SR, Parson HK, Nunnold T, Holton DR, Swain DP, Vinik AI: Change in cutaneous perfusion following 10 weeks of aerobic training in type 2 diabetes. J Diabetes Complications 19:276-283, 2005
18. Vinik AI, Erbas T, Park TS, Stansberry KB, Scanelli JA, Pittenger GL: Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care 24:1468-1475, 2001
19. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH: A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:150-154, 1993
20. McCarthy BG, Hsieh ST, Stocks A, Hauer P, Macko C, Cornblath DR, Griffin JW, McArthur JC: Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 45:1848-1855, 1995
21. Vinik AI, Suwanwalaikorn S, Stansberry KB, Holland MT, McNitt PM, Colen LE: Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve 18:574-584, 1995
22. Dyck PJ, Bushek W, Spring EM, Karnes JL, Litchy WJ, O'Brien PC, Service FJ: Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 10:432-440, 1987
23. Dyck PJ, Zimmerman I, Gillen DA, Johnson BS, Karnes JL, O'Brien PC: Cool, warm, and heat-pain detection thresholds. Neurology 43:1500-1508, 1993
24. Gruener G, Dyck PJ: Quantitative sensory testing: methodology, applications, and future directions. J Clin Neurophysiol 11:568-583, 1994
25. Dyck PJ, O'Brien PC, Kosanke JL, Gillen DA, Karnes JL: A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold. Neurology 43:1508-1512, 1993
26. Dyck PJ, Zimmerman IR, Johnson DM, Gillen D, Hokanson JL, Karnes JL, Gruener G, O'Brien PC: A standard test of heat-pain responses using CASE IV. J Neurol Sci 136:54-63, 1996
27. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, the American Diabetes Association: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956-962, 2005
28. Olney RK: Neurophysiologic evaluation and clinical trials for neuromuscular diseases. Muscle Nerve 21:1365-1367, 1998
29. Olney RK: Clinical trials for polyneuropathy: the role of nerve conduction studies, quantitative sensory testing, and autonomic function testing. J Clin Neurophysiol 15:129-137, 1998
30. Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI: The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 7:497-508, 2005
31. The PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54:2188-2197, 2005
32. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28:2686-2690, 2005
33. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE: Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 47:86-92, 2006
34. PKC-DRS2 Group; Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE: Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113:2221-2230, 2006
35. McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL: Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opin Drug Saf 5:835-845, 2006
36. Mellor H, Parker PJ: The extended protein kinase C superfamily. Biochem J 332:281-292, 1998
37. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728-731, 1996
38. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, Yasuda Y, Kamiya H, Ienaga K, Sakakibara F, Koh N, Hotta N: A protein kinase C β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48:2090-2095, 1999
39. Cameron NE, Cotter MA: Effects of protein kinase C beta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 18:315-323, 2002
40. Cotter MA, Jack AM, Cameron NE: Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 103:311-321, 2002
41. Vinik AI: Diabetic neuropathies: endpoints in clinical research studies. In Controversies in Diabetes Mellitus. Leroith D, Vinik AI, Eds. Totowa, NJ, Humana Press, 2006
42. Rice A, Vinik E, Barlow P, Ford-Molvik S, Vinik A: Topiramate treatment improves quality of life (QOL) and nerve function in patients with diabetic neuropathy (DN) (Abstract). Diabetes 55 (Suppl. 1):A131, 2006